Basic overview and review of the marketing history of perampanel tablets (perampanel)

Perampanel tablets (Perampanel) are oral prescription drugs used to treat epilepsy and are new anti-epileptic drugs (AEDs). Its mechanism of action is unique. As a selective non-competitive AMPA glutamate receptor antagonist, the AMPA receptor is a key channel mediating excitatory synaptic transmission in the central nervous system. Perampanel inhibits its excessive activation and reduces abnormal neuronal discharge, thereby effectively controlling epileptic seizures.

The drug was developed by the Japanese company Eisai (Eisai) and its trade name is Fycompa. In 2012, the US FDA was the first to approve it as an auxiliary treatment for partial seizures, suitable for epilepsy patients 12 years old and above. Since then, its indications have been continuously expanded to include generalized tonic - clonic seizures (GTCS) and partial epilepsy in children over 4 years old. In the same year, the European Medicines Agency (EMA) and the Japanese Ministry of Health, Labor and Welfare also approved its marketing.

Currently, perampanel has been approved for use in more than60 countries and regions around the world. It can be used as a single drug or as an adjuvant treatment. It shows good control effect and tolerability when many traditional anti-epileptic drugs are ineffective or have excessive side effects. It is recommended in several international epilepsy treatment guidelines due to its once-daily administration, long duration of action, and effectiveness against a variety of seizure types.

In China, perampanel was approved for import and marketing by the National Food and Drug Administration (NMPA) in 2019. It was originally developed and produced by Eisai Company, and the trade name is still Fycompa. Today, it is available in hospital pharmacies in several provinces for the treatment of partial and generalized seizures in patients 12 years of age and older. Although the process of including it in medical insurance is still advancing, in some cities, patients can obtain price support through special drug reimbursement or patient assistance programs to reduce the burden of medication.

Reference materials:https://www.drugs.com/mtm/perampanel.html